社区研究中阿尔茨海默病血液生物标志物与微血管病理及海马萎缩的磁共振表现频率
该研究在685名多族裔社区个体中检测血浆AD生物标志物(Aβ40、Aβ42、总tau、p-tau181、p-tau217、GFAP、NfL),并按既定cutoff分类AD生物标志物阳性与否,比较MRI上白质高信号体积、静息性脑梗死、微出血和海马体积。结果显示AD生物标志物阳性及其他痴呆个体白质高信号体积更大、梗死更多、海马更小,提示脑血管病与痴呆相关,建议联合血液标志物与结构影像评估。
要点
- AD血液生物标志物阳性者MRI显示更大白质高信号体积、更多梗死和更小海马。
- p-tau217阳性对白质高信号体积差异更敏感,p-tau181更好反映海马萎缩和静息性脑梗死。
- 族裔差异可能影响特定生物标志物与WMH体积、海马体积和梗死变化的检测。
核心结论
- 脑血管病直接参与痴呆或作为AD的共病病理持续存在。
- 评估痴呆患者需联合血液生物标志物与结构影像。
研究设计与样本
- 社区多族裔队列,685名有临床评估和脑MRI的个体,检测血浆Aβ40、Aβ42、总tau、p-tau181、p-tau217、GFAP和NfL。
- p-tau181组n=685,p-tau217组n=535,按既定cutoff(p-tau181 2.65 pg/mL,p-tau217 0.39 pg/mL)分类AD生物标志物阳性与否。
主要发现
- p-tau181组685人中70人(10.2%)为痴呆或遗忘型轻度认知障碍,其中40人(57%)AD生物标志物阳性,30人为其他痴呆。
- p-tau181组无痴呆615人中265人(40.3%)为临床前AD,348人(50.8%)为生物标志物阴性对照。
- p-tau217组535人中54人(10.1%)为痴呆或遗忘型轻度认知障碍,其中33人AD生物标志物阳性,21人为其他痴呆,183人(38.0%)为临床前AD,298人(61.9%)为生物标志物阴性对照。
- 两种分类下,AD生物标志物阳性和其他痴呆个体均显示更大WMH体积、更多梗死和更小海马。
关键数值与推荐
- AD生物标志物阳性cutoff:p-tau181 2.65 pg/mL,p-tau217 0.39 pg/mL。
- p-tau217阳性对WMH体积差异更敏感,p-tau181更好捕捉海马萎缩和静息性脑梗死。
临床怎么用
- 痴呆评估中应联合血液AD生物标志物与脑MRI结构影像。
- 关注脑血管病共病病理,尤其白质高信号、梗死和海马萎缩。
局限性
- 族裔差异可能影响生物标志物与影像变化的关联检测。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Blood-based biomarkers for Alzheimer's disease (AD), representing antemortem indicators of AD pathophysiology, have greatly improved the accuracy of diagnosis. However, these biomarkers may not capture a frequent coincident pathology, such as cerebrovascular disease. METHODS: We measured plasma amyloid-β40, amyloid-β42, total tau, tau phosphorylated at threonine 181, tau phosphorylated at threonine 217, glial fibrillary acidic protein, and neurofilament light chain in 685 multiancestral individuals who had clinical assessments and brain magnetic resonance imaging. The cohort was represented by individuals of European, African American, and Caribbean Hispanic ancestry. Participants were then classified as biomarker-positive or -negative for AD based on previously established cutoffs: 2.65 pg/mL for, tau phosphorylated at threonine 181 and 0.39 pg/mL for tau phosphorylated at threonine 217. We used magnetic resonance images to compare white matter hyperintensity volume (WMH), silent brain infarcts, microhemorrhages, and hippocampus volume across groups by their clinical diagnosis and biomarker status. RESULTS: In the P-tau181 group (n = 685), 70 individuals (10.2%) had dementia or amnestic mild cognitive impairment. A total of 40 (57%) were biomarker-positive for AD, and 30 were classified as other dementia. Among 615 without dementia, 265 (40.3%) were preclinical AD, and 348 (50.8%) were biomarker-negative controls. In the tau phosphorylated at threonine 217 group (n = 535), 54 (10.1%) had dementia or amnestic mild cognitive impairment, including 33 biomarker-positive for AD and 21 with other dementia, whereas 183 (38.0%) were preclinical AD and 298 (61.9%) were biomarker-negative controls. Across both classifications, biomarker-positive for AD and other dementia individuals showed greater WMH volumes, more infarcts, and smaller hippocampus. However, P-tau217 positivity was more sensitive to WMH volume differences, whereas tau phosphorylated at threonine 181 better captured hippocampal atrophy and silent brain infarcts. Interestingly, ethnic differences may also influence detection of changes in WMH volumes, hippocampal volume, and infarcts in relation to specific biomarkers. INTERPRETATION: The results indicate that cerebrovascular disease is consistently involved in dementia either directly or as a coincident pathology in AD. These results underscore the need to incorporate both blood-based biomarkers and structural imaging in the evaluation of patients with dementia. ANN NEUROL 2025;98:1027-1043.
引用
- Gunasekaran TI, Sanchez D, Reyes-Dumeyer D, et al. Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers. Ann Neurol. 2025. PMID: 40735976. doi:10.1002/ana.70006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。